News
ARWR ▲ +2.0% - Arrowhead Pharmaceuticals, Inc.
ARWR ▲ +2.0% - Arrowhead Pharmaceuticals, Inc.
$ARWR - Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
27-OCT-2026 11:45 AM ET
Share this post
More filings for $ARWR
ARWR ▲ +0.7% - Arrowhead Pharmaceuticals, Inc.Oct 15, 2026ARWR ▲ +3.0% - Arrowhead Pharmaceuticals, Inc.Oct 14, 2026ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.Oct 7, 2026ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.Oct 7, 2026ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc.Sep 15, 2026ARWR ▼ -0.8% - Arrowhead Pharmaceuticals, Inc.Sep 3, 2026
View full $ARWR filing history →💬 Comments
Loading comments…
Leave a comment